Technical Assessment Forms
Download Technical Assessment Forms (PDF)
TA Form | Required Test |
---|---|
GEN-CQD-003 |
All tests submitting a Technical Assessment UPDATED 10/17/2024 |
GEN-PF-001 |
Tests with results that are either novel or proprietary technology and/or algorithms. Tests that require an evaluation of clinical utility or clinical validity that is not already established in existing policies or standards of care. |
NGS-PF-004 |
NGS “Targeted” Panel – Solid Tumor and Solid Tumor, plasma-based NGS “Comprehensive Genomic Profile” – Solid Tumor and Solid Tumor, plasma-based |
NGS-PF-005 |
NGS “Targeted" Panel – Hematopoietic Malignancy NGS “Comprehensive Genomic Profile” – Hematopoietic Malignancy |
GER-PF-006 Formerly NGS-PF-006 |
Inherited Cancer Testing |
NGS-PF-002 Analytical Validity – Performance Specifications for Comprehensive Genomic Profiling Checklist, Somatic |
NGS “Comprehensive Genomic Profile” – Solid Tumor and Solid Tumor, plasma-based NGS “Comprehensive Genomic Profile” – Hematopoietic Malignancy |
MRD-PF-016 |
Minimal Residual Disease (MRD) Testing |
MRS-PF-020 |
Molecular Testing for Risk Stratification (MRS) Example: Biomarkers |
MID-PF-019 |
Molecular Testing for Syndromic Infectious Disease (MID) |
GER-PF-008 |
Inherited Germline Testing for Non-Cancer |
Venous Thromboembolism Risk and Hereditary Thrombophilia |
|
GER-PF-024 |
Whole Exome Sequencing (WES) Whole Genome Sequencing (WGS) NEW 10/17/2024 |
PCFS-PF-021 |
Prenatal cell-free DNA Screening (PCFS) |
PCS-PF-022 |
Prenatal Carrier Screening (PCS) |
PGX-PF-007 |
Pharmacogenomics (PGx) tests |
ALLO-CQ-003 |
Molecular Testing for Solid Organ Allograft Rejection |
ALLO-PF-009 |
Molecular Testing for Solid Organ Allograft Rejection |
GEN-PF-010 |
Required for tests that must be priced by Palmetto GBA |